The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported fourth-quarter net revenue of US$36 million, boosting full-year revenue to US$115 million for the period ended 30 June 2026.
What did Mesoblast report?
- Fourth quarter net revenue: US$36 million
- Full-year net revenue: US$115 million
- Ryoncil® uptake exceeded initial projections
- Strong capital position and funding for operations
What else do investors need to know?
Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the US FDA for any indication and remains the only FDA-approved option for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This achievement has positioned Mesoblast as a leading developer of allogeneic cellular medicines targeting severe inflammatory diseases.
The company’s manufacturing capabilities continue to deliver industrial-scale, off-the-shelf cellular medicines. Mesoblast also has an extensive intellectual property portfolio, with patents that provide commercial protection through to at least 2044 in key markets.
What’s next for Mesoblast?
Looking ahead, Mesoblast expects continued revenue growth, supported by momentum across major US paediatric centres. The company’s robust capital base and new five-year facility are intended to support further strategic initiatives, including label extensions and new blockbuster product launches.
Mesoblast is advancing its Ryoncil® therapy for additional inflammatory diseases, such as SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform targets heart failure and chronic low back pain.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 27%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.
The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia.
Should you invest $1,000 in Mesoblast right now?
Before you buy Mesoblast shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Mesoblast wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 16 June 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Ingenia Communities Group shares paused pending announcement
- Why brokers think Zip shares could soar 50% or more in FY27
- NEXTDC boosts funding with $2.3 billion senior debt facility upsize
- ASX 200 shares vs. US stocks in FY26
- 5 things to watch on the ASX 200 on Friday
Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.